EZH2 as a novel therapeutic target for atrial fibrosis and atrial fibrillation.
Song S, Zhang R, Mo B, Chen L, Liu L, Yu Y, Cao W, Fang G, Wan Y, Gu Y, Wang Y, Li Y, Yu Y, Wang Q.
Song S, et al.
J Mol Cell Cardiol. 2019 Oct;135:119-133. doi: 10.1016/j.yjmcc.2019.08.003. Epub 2019 Aug 10.
J Mol Cell Cardiol. 2019.
PMID: 31408621